In patients with adenocarcinoma of the esophagus who receive preoperative chemoradiotherapy (CRT), American Joint Committee on Cancer (AJCC) stage, pathologic complete response (pCR), and estimated treatment response are various means used to stratify patients prognostically after surgery. However, none of these methods has been formally evaluated. The purpose of this study was to establish prognostic pathologic variables after CRT.
INTRODUCTION
The benefit of induction chemoradiotherapy (CRT) followed by resection for patients with locally advanced esophageal cancer remains controversial, but this treatment paradigm is increasingly being used. 1 One of the many unresolved questions regarding this approach is how to restage patients after completion of their treatment. Accurate restaging of patients after CRT is important because it provides prognostic information, which can help direct subsequent treatment decisions. One frequently used method is simply to classify patients according to whether or not they have experienced a pathologic complete response (pCR). Indeed, many studies show that patients with a pCR have a better long-term prognosis than patients with residual disease.
2-6 Another method used to restage patients after CRT is to use the current American Joint Committee on Cancer (AJCC) staging system. 7, 8 Alternately, some investigators rely on the estimated treatment response as a means to stratify patients into prognostic groups. 9, 10 Each of these methods has limitations. Grouping patients into pCR versus residual disease ignores potentially diverse subsets of patients in the non-pCR group. However, the AJCC system has no stage for pCR, and it may ascribe too much weight to the depth of the primary tumor in patients in whom this may be difficult to measure after radiation. Lastly, estimation of treatment response is subjective and might not correspond to outcome.
In this article, we review our experience in a group of patients who received CRT followed by resection and explore the relationship between pathologic findings and overall survival. Because previously published data support the use of the number of involved lymph nodes for staging noninduction patients, 11 we include this variable in our analyses. In addition, because both the literature 6,12,13 and a preliminary analysis of our data indicate that adenocarcinoma and squamous cell carcinoma respond differently to CRT, we present data on adenocarcinoma only in this article.
PATIENTS AND METHODS

Acquisition of Clinical Data
We undertook a retrospective review of all patients undergoing resection for adenocarcinoma of the esophagus at Memorial Sloan-Kettering Cancer Center between January 1996 and June 2005. January 1996 is the time point at which an institutional electronic medical record system was instituted and is, therefore, a date from which highly reliable data can be obtained. Patients without survival information were excluded from this analysis. We also excluded any patient who did not undergo CRT or who underwent intended definitive nonsurgical therapy but was eventually resected (primary CRT).
The data collected included patient age, preoperative clinical stage (based on a combination of radiographic and endoscopic studies), type of CRT (type of chemotherapy, amount of radiation, and length of time from the completion of radiation to surgery), depth of tumor invasion, estimated treatment effect, and the number of all malignant and benign lymph nodes. Overall survival, as calculated from the time of operation, was obtained from the electronic records at Memorial Sloan-Kettering Cancer Center and confirmed by the Social Security Death Index. January 2006 was the censoring date for survival.
Clinical Stage
Patients treated with CRT at our institution are all deemed to have locoregional advanced-stage disease. Clinical confirmation of stage was performed with varying combinations of computed tomography scan, positron emission tomography scan, and endoscopic ultrasound (EUS). Evidence of lymph node involvement by computed tomography, positron emission tomography, or EUS and evidence of a T3 or N1 lesion by EUS were all used as evidence of regional disease. Patients with these findings were felt to have locally advanced disease (clinical stage II to IVA).
TNM Classification
The TNM descriptors and staging classification used for this analysis were those defined in the sixth edition of the AJCC Cancer Staging Manual. 8 Because of some variations in the nomenclature used by surgeons and pathologists in identifying the exact location of lymph nodes within a resected specimen, lymph nodes were consistently identified as celiac axis if they were labeled as left gastric, splenic, celiac, or hepatic. Within the chest, lymph nodes were identified as subcarinal lymph nodes if they were labeled as level 7, left mainstem, or right mainstem. M1a nodes were labeled according to the primary tumor location. Celiac axis nodes were M1a for distal esophageal, gastroesophageal junction, and gastric cardia tumors that involved the gastroesophageal junction. The total number of involved lymph nodes included any positive lymph node found excluding remote nodes that would be assigned as M1b. The overall number of lymph nodes included the sum of all positive lymph nodes plus all benign lymph nodes found. Disease was considered M1b if nodes were positive outside the regional basin or if visceral metastases were identified. Depth of invasion was assigned as described in the AJCC staging manual. pCR was assigned when no evidence of viable disease was noted (ie, T0N0). Patients with T0N1 disease were assigned as stage IIB. In the analyses, which used the number of involved lymph nodes as variables, the nomenclature used to distinguish from the AJCC nodal system is N(# ϩ ).
Estimation of Treatment Effect and pCR
The gross appearance of treated tumors varied from mucosal ulceration to a fibrous scar or a prominent mass lesion in the case of a less than profound tumor regression. The ulcerated or scarred gross lesion was blocked and sequentially and entirely submitted for histopathologic evaluation. When the tumor was large in size (Ͼ 5.0 cm), only representative sections of the tumor were examined microscopically. All pathologic specimens were rereviewed by a single pathologist (L.T.) who was blinded to patient outcomes, and the estimation of treatment response was subjective and based on the following criteria. At the microscopic level, a positive treatment-related effect was observed as abolition of the malignant epithelium and replacement by reactive fibrosis or fibroinflammation within the mucosa or the gastroesophageal wall. The ultimate pathologic response to treatment was determined by the amount of residual viable carcinoma in relation to areas of fibrosis or fibroinflammation within the gross lesion, which was inversely associated with, and expressed as percentage of, a favorable treatment response. Thus, a 100% treatment response indicated fibrosis or fibroinflammation within an entire gross lesion without microscopic evidence of carcinoma, and a 0% response represented an entirely viable tumor in the absence of any fibrosis of fibroinflammation. Acellular mucin was regarded as a form of positive treatment response and not as residual/viable tumor. A pCR was assigned when there was both a 100% local treatment response as well as no evidence of residual nodal involvement.
Statistical Analysis
Patient characteristics are described using tables for categoric data and medians and ranges for continuous variables. Survival time was measured from the date of surgery to the date of death or last follow-up. Survival curves were estimated using the Kaplan-Meier method. Maximum log-rank analysis 14 was used to determine the optimal cutoffs for lymph node numbers. Recursive partitioning 15 was used to develop a scheme to classify patients into stage categories. We used recursive partitioning modeling because the goal of a staging system is to group the patients into homogenous categories with respect to their prognosis (in this case, survival). Because several clinical characteristics (TNM stage and lymph node numbers) affect the prognosis of a patient, traditional multivariable modeling, such as Cox proportional hazards regression, to account for these covariates does not provide a simple way to group the patients by prognosis categories. However, recursive partitioning separates the patients at each step into two groups based on the covariate that gives the maximal separation with respect to their prognosis. In addition to providing an algorithm to group the patients into categories, it accounts for interactions between factors. Thus, recursive partitioning was used to develop a scheme classify patients into stage categories. Recursive partitioning was performed using the RPART routines of Therneau and Atkinson. 16 This algorithm partitions after scaling the survival times so as to fit an exponential model, and the hazard rates in the exponential-scaled times of terminal nodes are reported.
RESULTS
Clinical Data
During the study period, 856 esophagectomies were performed, and 276 were appropriate for further analysis. Four hundred eighty patients were excluded because they did not receive CRT. Other reasons for exclusion included the following: squamous cell carcinoma (n ϭ 93), underwent primary CRT (n ϭ 12), inadequate pathologic data (n ϭ 3), and inadequate survival data (n ϭ 3). Two hundred twenty-four patients (81.2%) had clinical evidence of regional disease before therapy. Two hundred eight patients (75.0%) received 50.4 Gy of radiation in daily fractions of 1.8 Gy over 28 treatments in a manner described in a previous publication. 17 Similarly, most patients (n ϭ 266, 95.3%) were administered various concurrent cisplatinbased chemotherapy regimens, following a protocol previously described 17 (Table 1) .
AJCC Staging System
According to the AJCC staging system, after treatment, 52 patients had a pCR and thus did not have a defined stage, 32 had stage I disease, 85 had stage IIA, 32 had stage IIB, 41 had stage III, 12 had stage IVA, and 22 had stage IVB (Table 2) . A Kaplan-Meier survival analysis shows that the AJCC staging system does not discriminate well between patients who are stages pCR to IIa (P ϭ .52), patients who are stages IIB to III (P ϭ .87), and patients who are stages IVA to IVB (P ϭ .30; Fig 1) .
Outcome in Patients With a pCR to Induction Therapy
Overall, 52 patients (18.8%) had evidence of a pCR at the time of surgery ( Table 2 ). The survival of pCR patients was significantly better than in patients who had residual disease. pCR patients had a 3-year survival rate of 70.4% compared with 41.8% in patients with residual disease (P ϭ .01; Fig 2) . Of note, the likelihood of a pCR was not influenced by the clinical stage of disease (P ϭ .23) or by the EUS assessment of depth of invasion (P ϭ .54; data not shown).
Recursive Partitioning Analysis of TNM
Analysis of survival using recursive partitioning methods and TNM category as variables shows that the initial stratification results from the presence of metastatic disease (M category; Fig 3) . The second level of stratification then distinguishes node-negative from node-positive patients. Within the subset of N0M0 patients, T0-1 patients did best (n ϭ 84; 3-year survival rate, 70.5%), followed by T2-4 patients (n ϭ 91; 3-year survival rate, 51.6%). Among the patients who were N1M0, depth of invasion (T0-1 v T2-4) again separated patients (3-year survival rate, 51.9% and 28.9%, respectively).
Recursive Partitioning Analysis of TNM and Number of Malignant Lymph Nodes
A recursive partitioning analysis that includes TNM category as well as the number of malignant lymph nodes as variables shows that involvement of more than one lymph node is the initial discriminator of survival (Fig 4) The best prognostic group (including the 52 patients with a pCR) had a 3-year survival rate of 70.3% (n ϭ 92), the next best prognostic group (n ϭ 87) had a 3-year survival rate of 52.4%, and the third best prognostic group had a 3-year survival rate of 32.2% (n ϭ 20). Patients with more than two involved lymph nodes and without metastatic disease (n ϭ 53), regardless of the depth of invasion, did poorly, with an estimated 3-year survival rate of 26.3%. This result was similar, however, to patients with T2-4N(1 ϩ )M0 tumors (P ϭ .35). Further reinforcing the importance of the presence of any involved lymph nodes in determining survival, an analysis that compared the survival of patients relative to the number of involved 
‫ء‬
Locally advanced: no evidence of computed tomography or positron emission tomography adenopathy, or Ͻ T3N1 by endoscopic ultrasound.
†Regionally advanced: computed tomography or positron emission tomography evidence of adenopathy or evidence of T3 or N1 by endoscopic ultrasound. lymph nodes showed a sharp decrease in survival when any lymph node was involved (Appendix Fig A1, online only) .
Estimated Treatment Response
Two hundred sixty-seven patients (96.7%) had adequate data with which to attribute a treatment response. The median treatment response was 90% (mean, 72%). The mean treatment response was higher in node-negative patients (n ϭ 185) than in node-positive patients (n ϭ 82; 76.4% v 62.1%, respectively; P Ͻ .001). The median interval of time from completion of radiation to surgery was 49 days (mean, 58 days). There was no correlation between treatment response and the interval between radiation completion and surgery (P ϭ .37; data not shown). Excluding patients with metastatic disease, median survival increased incrementally with increasing treatment response, with a steady increase in survival seen after a more than 50% treatment response (Appendix Fig A2A, online only) . When the treatment response was stratified by lymph node involvement, there remained a trend of improved survival with increasing treatment response, with a similar cutoff noted at approximately 50% treatment response. However, even more striking than this trend is the fact that the average survival in patients who are node negative, regardless of estimated treatment response, is better than the survival in their counterparts who are node positive (Appendix Figs A2B and A2C, online only). This underscores the importance of lymph node 1  1 1  111  1 1  1  1   2 2 2 2 2   2 2 2 2   2 22   2 2  22  22  2 2  2   2  2  2   3   33   3 333 33  33 3 3  3  3 3 3  3 3   3   3   3  3  3  3  3   3 3  33  3 3 3 3 3  3 3   3 3 3  3 3  3 3  3  3 involvement in determining outcome, even in the face of poor treatment response.
In summary, the most important prognostic factors after CRT were node and metastasis status, whereas depth of invasion had less of an impact on survival. Although using pCR identifies a subset of patients who have a better prognosis, using pCR alone fails to recognize a large number of patients with residual disease, namely T1N(0 ϩ ) patients, who have a similar prognosis. Furthermore, in patients with residual T2-4 disease, nodal status is an important determinant of outcome; in patients with one or more involved lymph node, survival decreases significantly compared with node-negative patients. Finally, although the estimated treatment response can predict survival, this gauge is less predictive than nodal status.
DISCUSSION
Although establishing the benefits of preoperative CRT for locally and regionally advanced esophageal cancer remains elusive, 1, 7, [18] [19] [20] one frequent finding in the many studies that have investigated this treatment strategy is that various subsets of patients seem to benefit significantly from CRT. Several studies show that patients who experience a pCR to CRT have a better prognosis than patients with residual disease.
2-6,10 However, other studies do not support this conclusion, 12, [21] [22] [23] [24] and some studies have associated the likelihood of a pCR with pretreatment clinical stage, thereby raising a question of selection bias. 25, 26 Similarly, some studies have shown that patients with a major response to therapy have improved outcomes compared with patients who do not have a major response, 9, 10, 27 whereas others have used pretherapy clinical staging to correlate downstaging with improved outcome.
28 Some studies have also noted that the presence of residual involved lymph nodes seems to predict a particularly poor outcome. 29, 30 What emerges from these varied results is that CRT before surgery creates subsets of patients whose prognosis is not well described by the current AJCC staging system. Likewise, crudely classifying patients as having either a pCR or residual disease is overly simplistic.
In this analysis, we found that, in patients with adenocarcinoma, the principal determinants of outcome after CRT and surgery are the involvement of lymph nodes and the presence of metastatic disease. Patients who have T0-1 lesions with one or no involved lymph nodes have the best prognosis, followed by patients with T2-4 lesions who are node negative. The small incremental difference in survival between patients who are N(1 ϩ ) and N(Ն2 ϩ ) does not warrant a distinction between these nodal groupings. Among some noteworthy aspects of these findings is that the number of patients in the best prognostic group is nearly twice the number of patients with a pCR. Furthermore, this analysis highlights the fact the AJCC staging system attributes too much importance to the depth of invasion, as evidenced by the poor discrimination in survival between stages pCR to IIa. Estimation of treatment response did show a correlation with outcome, but this association was less evident if the analysis was stratified by nodal status. Thus, in general, regardless of the estimated treatment response, lymph node status was more predictive of outcome.
Several other studies evaluating the impact of CRT arrived at similar conclusions. In a retrospective review of 47 patients with adenocarcinoma, Dunne et al 27 found that the only predictor of survival after CRT and surgery was lymph node status. Suntharalingam et al 26 similarly showed that patients (n ϭ 45) who became node negative after CRT had significantly improved survival compared with patients who had persistent involved lymph nodes. In a group of patients with various tumor histologies (three adenocarcinomas and 15 squamous cell carcinomas), Alexander et al 29 also demonstrate that residual nodal status is the most important predictor of outcome. In patients with adenocarcinoma (n ϭ 187), Gu et al 30 showed that the number of involved lymph nodes is an additional predictor of outcome, with two or more nodes predicting a worse outcome. Finally, Rice et al 28 retrospectively evaluated groups of patients with various tumor histologies who were downstaged from clinical N1 disease to pathologic N0 disease (n ϭ 37) and compared them to a matched group of patients with persistent N1 disease (n ϭ 32). They were able to show a significant difference in survival between the two groups. In most of these studies, the number of patients evaluated was small; three of the five studies were not stratified by histology; and only two studies included multivariable analyses that included other pathologic variables.
There are several advantages of our study compared with other published series. This series consists of a large number of patients (n ϭ 276) with uniform histology, with consistent clinical staging studies, central review by one pathologist, and treatment provided over a short and contemporary time span. These characteristics minimize the risk for confounding influences that might occur over a longer time interval.
In conclusion, this study shows that, in patients with adenocarcinoma of the esophagus who are treated with preoperative CRT, current pathologic staging criteria (AJCC) do not adequately stratify prognostic groups. Furthermore, patients currently ascribed as having a pCR have similar outcomes as patients with residual T1 disease, and therefore, these two groups should be combined. Finally, in patients with residual T2-4 disease, prognostic groups should be stratified by nodal status (N0, N1). Although estimating tumor response provides additional information about prognosis, these additional data are outweighed by the importance of the nodal status. 
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